NCT01497860View on ClinicalTrials.gov

Vinorelbine for Children With Progressive or Recurrent Low-grade Gliomas

PHASE2CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

July 31, 2011

Primary Completion Date

January 31, 2017

Study Completion Date

July 31, 2017

Conditions
Low-grade Glioma
Interventions
DRUG

Vinorelbine

IV Vinorelbine (6mg/m2) provided once a week for 6 weeks followed by a 2 week rest (6 of every 8 weeks) for one year. Progression free survival will be monitored for 60 months.

Trial Locations (2)

20010

Children's National Medical Center, Washington D.C.

55905

Mayo Clinic, Rochester

All Listed Sponsors
lead

Eugene Hwang

OTHER

NCT01497860 - Vinorelbine for Children With Progressive or Recurrent Low-grade Gliomas | Biotech Hunter | Biotech Hunter